Weiss Ratings Reaffirms "Sell (D-)" Rating for Eton Pharmaceuticals (NASDAQ:ETON)

Key Points

• Weiss Ratings has reiterated a "Sell (D-)" rating for Eton Pharmaceuticals (NASDAQ:ETON) as of Wednesday.
• Contrastingly, Wall Street Zen raised Eton's rating from "Hold" to "Buy," leading to a consensus rating of "Moderate Buy" with an average target price of $29.67.
• Eton Pharmaceuticals recently reported a loss of $0.10 EPS for the quarter, missing analyst expectations, despite generating $18.93 million in revenue.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report)'s stock had its "sell (d-)" rating reiterated by stock analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of Eton Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Eton Pharmaceuticals has a consensus rating of "Moderate Buy" and an average target price of $29.67.

Eton Pharmaceuticals Stock Down 1.0%

ETON stock opened at $20.93 on Wednesday. Eton Pharmaceuticals has a twelve month low of $7.25 and a twelve month high of $23.00. The stock's 50 day moving average is $17.85 and its 200-day moving average is $16.21. The company has a quick ratio of 1.16, a current ratio of 1.77 and a debt-to-equity ratio of 1.14. The firm has a market capitalization of $561.34 million, a PE ratio of -130.81 and a beta of 1.16.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.09). Eton Pharmaceuticals had a negative return on equity of 0.73% and a negative net margin of 7.10%.The firm had revenue of $18.93 million for the quarter, compared to the consensus estimate of $16.71 million. Sell-side analysts expect that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In other news, CFO James R. Gruber sold 39,082 shares of the business's stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $16.16, for a total transaction of $631,565.12. Following the completion of the transaction, the chief financial officer directly owned 205,299 shares in the company, valued at $3,317,631.84. The trade was a 15.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 16.03% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Ameritas Investment Partners Inc. purchased a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at $37,000. Legal & General Group Plc purchased a new position in Eton Pharmaceuticals in the second quarter worth $41,000. AlphaQuest LLC purchased a new position in Eton Pharmaceuticals in the first quarter worth $53,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Eton Pharmaceuticals in the second quarter worth $87,000. Finally, Quantbot Technologies LP purchased a new position in Eton Pharmaceuticals in the first quarter worth $101,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.